Patients with candidemia may have transient or catheter-related infections without involvement of deep tissues or deep-seated candidiasis. Clinical differentiation of these entities may not be evident with conventional microbiological and imaging methods. Our aim was to determine if the detection of Candida albicans germ tube-specific antibody (CAGTA) in patients with candidemia was related to the extent of the disease. This study was conducted from 2003 to 2012 with 50 patients diagnosed as having candidemia, that is, 29 with deep-seated candidiasis and 21 with non-deep-seated candidiasis. The most common species recovered from samples obtained from these patients were C. albicans, 40%; C. tropicalis, 20%; C. parapsilosis, 18%; and C. glabrata, 12%. Serum samples were processed according to the manufacturer's recommendations (Vircell Microbiologist S.L., Granada, Spain). The CAGTA tests were positive in 1/21 non-deep-seated candidemias (DSCs; 4.76%) and 20/29 DSCs (68.96%; P < 0.01). Accordingly, the values for specificity and positive predictive values of CAGTA for identifying DSC were 95%. We concluded that the presence of a positive CAGTA test in a sample from a patient with candidemia suggests deep-seated candidiasis. Extension screening studies should be considered and origins other than catheters should be searched. Prospective studies are needed to determine the clinical implications of this finding and its potential use in defining the optimal duration of therapy.
Introduction
Patients with candidemia may have transient or catheterrelated infections without involvement of deep tissues or deep-seated candidiasis [1, 2] . Clinical differentiation of these entities may not be evident with conventional microbiological and imaging methods. The identification of these subpopulations by means of circulating surrogate biomarkers could be useful to indicate the need for extension screening tests and even to help determine the length of therapy.
Candida albicans germ tube-specific antibody (invasive candidiasis [CAGTA] immunofluorescence assay (IFA) immunoglobulin G [IgG] ; Vircell Microbiologist S.L., Granada, Spain) is a commercially available indirect immunofluorescence test that allows the detection of antimycelium antibodies against several Candida spp. The detection of CAGTA in serum specimens of patients with candidemia and/or invasive candidiasis has shown a sensitivity of 84.4%-96% and a specificity of 94.7%-100% [3, 4] . The test has also been assayed in serum samples from hematologically and critically ill patients at risk of invasive candidiasis, showing high sensitivity (84%-87%) and specificity (94.7%-95%) [5, 6] .
Positive serum CAGTA detection is suggestive of deepseated candidiasis in which Candida hyphae invade different body tissues [7, 8] . Hyphae contain hpw1 antigens that promote the production of CAGTA [9, 10] . Our hypothesis was that patients with candidemia and a positive CAGTA should be considered as having invasive candidiasis. The results presented here confirm this theory.
Material and methods
The study included 50 adult patients who were diagnosed as having candidemia between 2003 and 2012 and had available serum samples that were collected within 48 h after the initial diagnosis of candidemia. Serum samples were also obtained from a control group of 50 healthy individuals. All samples were stored at −70 o C until processing.
Candidemia was defined as the isolation of Candida spp. from at least one blood specimen obtained from a peripheral vein [11] . We defined proven deep-seated candidemia (DSC), following Leroy et al. [12] , as the isolation of a yeast from at least one sample, as well as its recovery from another specimen from a normally sterile site that is related to a speciffic focus on infection. We also accepted as probable DSC, patients with candidemia and a clinically documented site of infection without microbiological confirmation of Candida spp. and no other etiology, for example, candidemic patients with chorioretinitis or intraabdominal infection. The source of candidemia was established according to standard clinical, imaging, and microbiological criteria. Each case was reviewed independently by three investigators blind to the CAGTA results.
Candida species was identified using ID 32C (bioMérieux, Marcy l'Etoile, France). Clinical characteristics of the episodes were obtained from our database of bloodstream infections, and all records were reviewed according to a preestablished protocol. Demographic information and presence of underlying conditions were recorded.
Serological detection of CAGTA
Serum samples were processed according to the manufacturer's recommendations (Vircell Microbiologist S.L., Granada, Spain). Briefly, serum samples were diluted (1:4) in phosphate-buffered saline; 20 µl of the resulting solution was added to 80 µL of sorbent (Candida albicans aliquots in yeast phase) to achieve a 1:20 dilution of the sample. A total of 20 µl of this solution was deposited in each well of the slide where Candida albicans mycelial-phase antigens were fixed. Subsequently, antihuman IgG antibodies labeled with fluorescein were added. The samples were interpreted as positive if green fluorescence was observed at the mycelial phase and blastoconidias were stained red. Positive samples were diluted to obtain the titer. Samples were positive considering a cutoff ≥1/160. Indeterminate results were retested, and the second result was considered.
Statistical analysis
Patients with and without DSC were compared. We used the two-tailed Fisher exact test to study the correlation between CAGTA positivity and DSC. Sensitivity, specificity, positive and negative predictive values, and accuracy of the CAGTA test for the diagnosis of DSC were studied. A P value < 0.05 was considered statistically significant. Data were entered in a database created using Access 2003, and SPSS 16.0 was used for statistical analysis (IBM, SPPS Statistic; Armonk, New York).
Ethical and legal issues
The study was approved by the local ethics committee (CEIC-A1 (Comitéético de investigación científica delÁrea 1 del Hospital General Universitario Gregorio Marañón), Ref. 350/12) and by the Spanish competent authorities (Agencia Española del Medicamento y Productos Sanitarios). Due to the retrospective design of the study, the ethics committee waived the need for informed consent from study participants.
Results
The patients' demographic and clinical data are summarized in Table 1 .. Mean age of the patient population was 64.6 ± 15.6 years and their main underlying conditions were gastrointestinal diseases (52%) and solid tumors (40%). Risk factors for candidemia included, among others, the use of intravascular catheters (96%), recent surgery (52%), indwelling bladder catheters (46%), and total parenteral nutrition (40%). Most commonly recovered species were C. albicans (40%) and C. tropicalis (20%). Overall, 46% of the patients died during their hospitalization.
Of the 50 episodes of candidemia, 21 (42%) were classified as non-DSC, including 16 catheter-related infections (76.2%) and 5 primary fungemias. The remaining 29 cases were considered to be DSC, with most of these patients having intraabdominal (14) or urinary tract infections with obstruction (8) . Additional sites of infection included three endovascular, two chorioretinitis, two perianal cellulitis in neutropenic patients, and one case each of meningitis, empyema, vertebral osteomyelitis, and disseminated skin lesions, with four patients having infections at more than one site.
Overall, 16 DSC cases were microbiologically proven (55.2%) and 13 were clinically diagnosed (1 nonoperated endocarditis, 1 chorioretinitis, 1 urologic sepsis, and 10 intraabdominal candidiasis), with no sample sent to the microbiology laboratory for analysis.
Overall, 21/50 serum samples obtained within 48 h of the candidemia (42%) were found to be positive with the CAGTA, of which 1/21 specimens were obtained from a patient with non-DSC and 20/29 of samples from DSC individuals (4.76% vs. 68.96%; P < 0.01; Table 2 ).
The patient classified as non-DSC who presented a "false-positive" CAGTA was a 53-year-old male diagnosed with idiopathic thrombocytopenic purpura after suffering two neurological events for which he was receiving rituximab. He required multiple intensive care unit (ICU) admissions and plasmapheresis and remained in the hospital for 6 months. We were able to demonstrate only catheterrelated candidemia (catheter hub and blood cultures both with C. albicans), although other sources could not be completely excluded due to his terminal condition.
The nine patients with DSC and false-negative CAGTAs corresponded to five immunosuppressed patients (two infected with human immunodeficiency virus and three hematological patients), three patients with neoplasia (one hepatocarcinoma and two gastric cancers), and one patient with advanced diabetes mellitus and permanent indwelling bladder catheter. False-negative CAGTA was significantly associated with immunosuppression (83.3% vs. 17.4%; P < 0.01), severity of the disease as reflected in the Pitt score (4 ± 3.8 vs. 1.9 ± 2; P = 0.06), need for mechanical ventilation (71.4% vs. 19.2%; P = 0.008), and candidemia caused by C. krusei or C. tropicalis (75% vs. 14.3%; P = 0.004).
The overall mortality rate was similar in patients with negative and positive CAGTA: 48% vs. 43%; P = 0.8. However, early mortality (first 7 days) was higher in patients with negative CAGTA (34.5% vs. 9.5%; P = 0.04). We did not find a clear association between CAGTA titers and overall mortality: negative CAGTA: 14/29 (48.3%), 1/160: 3/9 (33.3%), >1/160: 6/12 (50%); P = 0.7. Early mortality rates in patients with different CAGTA titers were as follows: negative CAGTA (<1/160): 34.5%, 1/160: 0%, >1/160: 16.7%; P = 0.08.
Control group
The average age of the 50 healthy individuals in the control group was 38.5 ± 11.6 years, and 16 (32%) were men. None had an active infection at the time of the study, with the exception of one person who suffered from recurrent Candida vaginitis. All control samples yielded negative CAGTA determinations (≤ 1/20).
Discussion
Our data show that a positive CAGTA result in a patient with candidemia is very suggestive of deep-seated candidiasis, which may have diagnostic and therapeutic implications.
Recent studies indicate that patients with invasive candidiasis should be classified into the following three groups: candidemia without deep-seated candidiasis, candidemia associated with deep-seated candidiasis, and deep-seated candidiasis not associated with candidemia. In a recent study performed in French ICUs, it was found that 39.5% of the patients were classified as having isolated candidemia, 28.4% as having candidemia with invasive candidiasis, and 32.1% as having invasive candidiasis without documented candidemia [12] . Considering that blood cultures are estimated to have a sensitivity of 50% when diagnosing invasive candidiasis, nonculture methods will disclose half of the deep-seated candidiasis in the second group and all cases in the third group [1] .
It may be difficult to differentiate between candidemic patients with or without deep-seated candidiasis when clinical manifestations are unspecific or when invasive sampling procedures are contraindicated. Cultures inoculated with samples from deep tissues may also become negative after some days of antifungal therapy. The identification of DSC is important because these patients may require more prolonged therapy or surgical debridement. The potential use of nonculture diagnostic tests for DSC has been emphasized in a recent study by Nguyen et al. [2] . Blood cultures, beta-D-glucan assay (BDG), and a quantitative real-time polymerase chain reaction (RT-PCR) assay were compared in a population in which 60% of patients had DSC in the absence of positive blood cultures. Both PCR and BDG proved to be superior to blood cultures among patients with DSC (88% and 62% vs. 17%, respectively). Girmenia et al. reported that mannoproteinemia was observed in 7% of patients with transient or catheter-related candidemia but in 76% of patients with persistent candidemia or invasive candidiasis [13] . We believe that in the near future, the proportion of patients with invasive candidiasis but without candidemia will increase with the widespread adoption of new diagnostic techniques.
The CAGTA test consists of an immunofluorescence assay to detect antibodies against an antigen of the mycelial phase of C. albicans, hwp1, that is essential for biofilm development and tissue invasion [3, 14, 15] . Although the technique was originally designed for C. albicans, it has been shown that other Candida species, including C. tropicalis, C. parapsilosis, C. glabrata, C. dubliniensis, C. guilliermondii, and C. krusei, are able to produce CAGTA to a greater or lesser degree [3, 7, 16, 17] . In our experience, the accuracy of the CAGTA test was similar for all Candida species, with the exception of C. tropicalis, which showed a lower sensitivity (33%) and retained a very high specificity (100%). The reason for this apparent lower accuracy of CAGTA remains to be investigated. CAGTA yielded an S of 75% with 100% Sp for C. glabrata candidemias, despite the fact that this yeast has never been shown to produce hyphae. However, it may produce pseudohyphae, which could account for the positive CAGTA result [18] . A positive CAGTA test is thus suggestive of deep-seated disease caused by any of these species.
Suggested cutoffs differ with the type of patient, 1/20 is recommended for hematological patients and 1/160 for all other patients [3, 5] . One advantage of this technique when compared with other nonculture diagnostic methods is its reduced price (approximately 10 € ($13.65 US) per determination) and its relatively rapid turnover (3 h total, with 20 min of hands-on time).
There are not many clinical studies of the use of this test and no published reports correlate the production of CAGTA with the source or the extent of Candida bloodstream infection. Pemán and colleagues suggested that systematic CAGTA serum determinations from critically ill patients at risk of invasive candidiasis were good markers for administration of empirical antifungal drugs [6] . The test may also be useful when measuring the response to antifungal treatment in this group of patients [19] and could even help predict patient outcomes. In our series, the mortality rate was similar in patients with and without DSC candidemia (47% and 44%, respectively). These results are in agreement with those of Leroy et al., who reported fatal outcomes of 47.7% among patients with isolated candidemia, 48.7% in candidemic patients with invasive candidiasis, and 41% in patients with invasive candidiasis without documented candidemia [12] . However, patients who died within the first 7 days after candidemia usually had a negative CAGTA. Other authors have also found that intra-ICU mortality rate was lower in CAGTA-positive patients [19, 20] .
In future studies, the role of CAGTA in patients with deep-seated candidiasis without candidemia needs to be established, as well as its performance in immunosuppressed patients in whom we observed a higher rate of false-negative results.
Our study has limitations that might have effected the results and their interpretations. First, it is a retrospective analysis in which blood for CAGTA was analyzed only once, so the test could not be evaluated for disease screening or therapy response. Second, we were able to study only a relatively small number of cases. However, to the best of our knowledge, this is the first time that serum CAGTA determinations were used to discriminate the extent of tissue infection in patients with candidemia.
We conclude that the presence of a positive CAGTA test in a patient with candidemia is an indication that the patient has deep-seated candidiasis. Under these circumstances, extension screening studies should be performed and origins other than catheters should be searched. Prospective studies that include a larger number of patients, serial samples, and combination of different nonculture techniques are needed in order to determine the clinical implications of this finding and its potential utility in defining the optimal duration of therapy.
